

Susan E. Alters, Ph.D.

Recent Abstracts and Presentations

Susan E. Alters, Alvin Wong, Alshad Lalani, and W.D. Henner, "The targeted cytotoxic prodrug, AQ4N, has significant activity in the breast adenocarcinoma model, MDA-MD-231." Presented at the AACR annual meeting, April, 2006.

Susan E. Alters, Alvin Wong, Alshad Lalani, and W.D. Henner, "The cytotoxic prodrug, AQ4N, demonstrates tumor targeting and accumulation resulting in anti-tumor activity in the BxPC3 pancreatic xenograft model." Presented at the AACR annual meeting, April, 2006.

Bart A Nijmeijer, Marianke LJ Van Schie, **Susan E Alters**, Alvin Wong, Jeffrey L Cleland, Roelof Willemze and J.H. Frederik Falkenburg, "The prodrug AQ4N displays potent anti-tumor activity in a xenotransplantation model of primary human acute lymphoblastic leukemia." Presented at the American Society for Hematology annual meeting, December, 2005.

Susan E. Alters, Jeffrey L. Cleland, Alvin Wong and W. David Henner, "The tissue targeted prodrug, AQ4N, is activated to AQ4 in murine tissues and has anti-tumor efficacy in HCT116 colon and Panc-1 pancreatic carcinoma xenograft models." Presented at the AACR/EORTC/NCI meeting, November, 2005.

Jeffrey L. Cleland, **Susan E. Alters** and Alvin Wong, "The tissue targeted cytotoxic prodrug, AQ4N, is an effective single agent therapy in solid tumor and leukemia models." Presented at the Controlled Release Society meeting, July, 2005.

Susan E. Alters, Alvin Wong, and Jeffrey L. Cleland, "The targeted cytotoxic prodrug, AQ4N, has anti-tumor efficacy in L1210, P388 murine leukemia and Namalwa human lymphoma models." Presented at the AACR annual meeting, April, 2005.

Jeffrey L. Cleland, Alvin Wong, and **Susan E. Alters**, "The targeted cytotoxic prodrug, AQ4N, has comparable activity to standard of care agents in colon and pancreatic cancer models." Presented at the AACR annual meeting, April, 2005.

Jeffrey L. Cleland, Alvin Wong, and **Susan E. Alters**, "The targeted cytotoxic prodrug, AQ4N, persists in the spleen, large intestine, and subcutaneous tumors." Presented at the AACR annual meeting, April, 2005.

Susan E. Alters, Alvin Wong, and Jeffrey L. Cleland, "A novel N-oxide drug, AQ4N, demonstrates in vitro cytotoxicity on solid tumor and hematopoietic tumor cell lines" Presented at the Experimental Biology annual meeting, April, 2005.

Jeffrey L. Cleland, Alvin Wong, **Susan E. Alters**, John G. Curd, Robert L. Capizzi, and William D. Henner, "A Novel N-Oxide Drug, AQ4N, Has In Vitro Activity in Lymphoma and Leukemia Cell Lines and Selectively Targets Lymphocytes and Lymphatic Tissues In Vivo." Presented at the American Society for Hematology annual meeting, Dec, 2004.